SpyVLP Clinically Validated

Multivalent VLP vaccines, built on a covalent protein superglue.

HBsAg-based virus-like particles densely decorated with antigens via the irreversible SpyCatcher/SpyTag isopeptide bond. Two clinical-inflection assets. Manufacturing-ready CMC. Pandemic-grade modularity.

The Technology

A scaffold that displays anything, made stable by chemistry.

The hepatitis B surface antigen (HBsAg) self-assembles into ~22 nm VLPs — a manufacturing-proven scaffold used in licensed vaccines for decades. SpyVLP fuses SpyCatcher domains to each HBsAg subunit. Any antigen of interest is expressed with a 13-residue SpyTag and mixed with the scaffold: the two halves form an irreversible isopeptide bond on contact.

SpyVLP virus-like particle with plug-and-display antigens

How it works

One scaffold. Any antigen. The covalent bond means stable, high-valency presentation in vivo — the geometry that drives germinal-centre B-cell selection and durable antibody responses.

  • Irreversible covalent display — the isopeptide bond is the only such linkage of its class; non-cleavable in serum.
  • Plug-and-play modularity — swap antigens without re-engineering scaffold, manufacturing, or CMC.
  • Multi-antigen cocktails — co-display multiple antigens for broad strain or pathogen coverage on one particle.
  • Cell-agnostic manufacturing — both halves can be produced in E. coli, yeast, insect, or mammalian — whichever system is best for each antigen.
< 6 mo
Antigen-to-IND-ready candidate
Phase II
Clinically validated platform
HBsAg
Scaffold with decades of GMP precedent
100s
Antigens covalently displayed per particle
SpyVLP Pipeline

Two clinical-inflection assets, anchored by CMV.

SPYVLP01 (CMV) is the lead asset, Phase II Ready. SPYVLP02 (EBV) follows close behind, Phase I Ready and addressing the EBV-MS causal link.

Candidate Platform Target Indication Stage
SPYVLP01 SpyVLP CMV (Cytomegalovirus) Congenital infection prevention Phase II Ready
SPYVLP02 SpyVLP EBV (Epstein-Barr Virus) IM prevention / MS risk reduction Phase I Ready
Get in touch about BD & partnerships